CliffBio
small molecule

BUNAVAIL

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

Loss of exclusivityApril 2035latest FDA-listed patent expiry
CompanyBioDelivery Sciences International →View the full company profile on CliffBio

Drug detail

Brand nameBUNAVAIL
Active ingredientBUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE
StrengthEQ 4.2MG BASE;EQ 0.7MG BASE
Dosage formFILM
RouteBUCCAL
ModalitySmall molecule
FDA approvalJune 2014
Marketing statusDISCN

Listed patents

PatentExpiresType
9522188April 2035product
8703177August 2032product
8147866July 2027product
9655843July 2027product

More from BioDelivery Sciences International

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

BUNAVAIL patent cliff — loss of exclusivity April 2035 | CliffBio